A 2025 PMC-published narrative review confirmed BPC-157's preclinical evidence in orthopaedic and sports medicine research, noting improvements in tendon healing and tendon-to-bone integration in animal models
www.nature.com , Li, A., Shi, Y., Xu, L., Zhang, Y., Zhao, H., Li, Q., Zhao, X., Cao, X., Zheng, H., & He, Y
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors not yet approved by the MHRA or EMA as of April 2025
Side Effects Both tirzepatide and semaglutide share similar side effects, including nausea, diarrhea, and stomach discomfort
STEP 1 phase 3 trial (n=1,961, 68 weeks), once-weekly Wegovy 2.4 mg produced a mean body weight reduction of 14.9%, compared to 2.4% with placebo
Dose-dependent effects: CBDAs pharmacology can vary with concentration, as with CBGA, requiring careful characterization in future studies